npj Metabolic Health and Disease

Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss

At a glance

For most diagnosis groups studied, later incidence was more strongly associated with maximum attained dose; cognitive and speech symptoms were exceptions that tracked more with weight loss.

The research question

Are later neuropsychiatric outcomes more closely associated with attained semaglutide dose or with achieved weight loss?

Overview

An observational analysis of 63,215 semaglutide-treated patients with baseline neuropsychiatric conditions compared later outcomes by attained dose and weight change. Higher doses were associated with lower incidence of several diagnosis groups; dementia incidence did not differ significantly.

Study design & methods

The researchers identified 489,785 semaglutide-treated patients in a federated EHR network and assembled 63,215 with baseline neuropsychiatric conditions. Bulk and single-cell transcriptomic datasets were used to map GLP1R expression in brain regions and peripheral nerves as contextual, not causal, evidence.

Associations differed across outcome domains

Semaglutide was associated with lower two-year risk than metformin for several affective, substance-use, vascular and cognitive-neurological outcomes. Compared with metformin, incident mood disorders were documented in 10.5% of semaglutide patients and 13.2% of matched controls during the initial two-year period.

Dose-stratified neuropsychiatric event probabilities and corresponding two-year event rates

Limitations & interpretation

Published in npj Metabolic Health and Disease. These observational associations do not establish a pharmacologic dose response: attained dose also reflects tolerability, adherence, access, and persistence. Healthy-adherer bias and residual confounding may explain part of the pattern. Transcriptomic findings provide exploratory context, not proof of a brain mechanism.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
NeurosciencePeer-Reviewed Journal Publication

Somatosensory and peripheral neuropathic outcomes after semaglutide or tirzepatide initiation compared with other anti-diabetic medications

In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.

Biology Methods and Protocols
November 4, 2026
NeurosciencePeer-Reviewed Journal Publication

GLP-1–based incretin therapy is associated with lower incident Alzheimer’s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk

In adults aged 50 or older with documented Alzheimer’s risk factors, a matched target-trial emulation found lower recorded Alzheimer’s incidence after GLP-1–based incretin initiation than after non-GLP-1 antidiabetic treatment. The observational design cannot establish prevention or causality.

Biology Methods and Protocols
August 3, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.